Publication:
Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy with Hypercholesterolemia: A Randomized Controlled Trial

Issued Date

2016-09-15

Resource Type

Conference Paper

ISSN

15376591
10584838

DOI

10.1093/cid/ciw395

Other identifier(s)

2-s2.0-84995467105

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

Clinical Infectious Diseases. Vol.63, No.6 (2016), 818-820

Suggested Citation

Phanthaboon Wangpatharawanit, Somnuek Sungkanuparph Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy with Hypercholesterolemia: A Randomized Controlled Trial. Clinical Infectious Diseases. Vol.63, No.6 (2016), 818-820. doi:10.1093/cid/ciw395 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/41150

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy with Hypercholesterolemia: A Randomized Controlled Trial

Author(s)

Phanthaboon Wangpatharawanit
 Somnuek Sungkanuparph

Other Contributor(s)

Mahidol University

Abstract

© 2016 The Author. A randomized controlled trial was conducted among human immunodeficiency virus-infected patients receiving lopinavir/ritonavir-based regimens with hypercholesterolemia. Reduction of total cholesterol and low-density lipoprotein was significantly greater in patients who were randomized to the addition of atorvastatin compared with those who were switched from lopinavir/ritonavir to atazanavir/ritonavir.

Keyword(s)

Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/123456789/41150

Collections

Scopus 2016-2017